Viatris Comes Out Swinging At Unsolicited Mini-Tender Offer
TRC Capital Makes Discounted Offer For Millions Of Shares
Executive Summary
TRC Capital Corporation, famed for making discounted offers to buy shares well below the SEC’s 5% threshold, has approached Viatris shareholders. The newly-formed company, like many others, has urged shareholders to say no.
You may also be interested in...
Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: